A new tool in the fight against autoimmune disease lupus
There is a new way to detect lupus before it causes more significant damage. LuGENE, a new blood test by AMPEL BioSolutions, helps forecast flare-ups and recognizes targets for effective drug options based on genomic data it reveals.
AMPEL BioSolutions Building Evidence for Prognostic Potential of Lupus Molecular Subtyping Test
AMPEL BioSolutions is recruiting individuals with systemic lupus erythematosus (SLE) into an observational study of its blood-based prognostic gene expression assay LuGene to demonstrate a correlation between test results and standard clinical evaluations.
New Lupus Test Predicts Flares & Drug Targets
From RNA gene expression in cells circulating in the blood, LuGENE identifies real-time abnormalities leading to inflammation and immune system dysfunction that are targetable by medication.
Revolutionizing Lupus Care with Advanced Predictive Blood Testing
AMPEL BioSolutions introduces LuGENE®, a cutting-edge blood test poised to revolutionize the management of systematic lupus erythematosus (SLE). LuGENE® leverages predictive artificial intelligence (AI) to detect genetic biomarkers indicative of inflammation-driven SLE flares, offering clinicians valuable insights for tailored treatment strategies.
LuGENE Launches in LA: Podcast with Dr. Dan Wallace
This #NewsFromTheLab session welcomes the creators of the new LuGENE lab test by Ampel BioSolutions! Watch Dr. Amrie Grammer and Dr. Peter Lipsky share about the cutting-edge LuGENE® Blood Test, a revolutionary tool designed to predict flare activity and drug targets in lupus, offering new hope and possibilities for patients.